메뉴 건너뛰기




Volumn 135, Issue 1, 2011, Pages 173-174

Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

EID: 79251504278     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPFMV43IFPRTWK     Document Type: Letter
Times cited : (4)

References (14)
  • 1
    • 73949120475 scopus 로고    scopus 로고
    • Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia
    • Chang H, Jiang AM, Qi CX. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia. Am J Clin Pathol. 2010;133:70-74.
    • (2010) Am J Clin Pathol , vol.133 , pp. 70-74
    • Chang, H.1    Jiang, A.M.2    Qi, C.X.3
  • 3
    • 54049141334 scopus 로고    scopus 로고
    • Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up
    • Zenz T, Kröber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322-3329.
    • (2008) Blood , vol.112 , pp. 3322-3329
    • Zenz, T.1    Kröber, A.2    Scherer, K.3
  • 4
    • 61549089361 scopus 로고    scopus 로고
    • The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: Implications for overall survival and chemorefractoriness
    • Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15:995-1004.
    • (2009) Clin Cancer Res , vol.15 , pp. 995-1004
    • Rossi, D.1    Cerri, M.2    Deambrogi, C.3
  • 5
    • 0028085611 scopus 로고
    • Detection of p53 mutations in hematological malignancies: Comparison between immunocytochemistry and DNA analysis
    • Lepelley P, Preudhomme C, Vanrumbeke M, et al. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia. 1994;8:1342-1349. (Pubitemid 24262491)
    • (1994) Leukemia , vol.8 , Issue.8 , pp. 1342-1349
    • Lepelley, P.1    Preudhomme, C.2    Vanrumbeke, M.3    Quesnel, B.4    Cosson, A.5    Fenaux, P.6
  • 7
    • 0037103257 scopus 로고    scopus 로고
    • Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors
    • Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-1184.
    • (2002) Blood , vol.100 , pp. 1177-1184
    • Oscier, D.G.1    Gardiner, A.C.2    Mould, S.J.3
  • 9
    • 0028987180 scopus 로고
    • p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
    • Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
    • (1995) Blood , vol.85 , pp. 1580-1589
    • Dohner, H.1    Fischer, K.2    Bentz, M.3
  • 11
    • 0025951144 scopus 로고
    • p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia
    • Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1991;88:5413-5417.
    • (1991) Proc Natl Acad Sci U S A , vol.88 , pp. 5413-5417
    • Gaidano, G.1    Ballerini, P.2    Gong, J.Z.3
  • 12
    • 0042744791 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features
    • Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood. 2003;102:1035-1041.
    • (2003) Blood , vol.102 , pp. 1035-1041
    • Guarini, A.1    Gaidano, G.2    Mauro, F.R.3
  • 13
    • 0028071555 scopus 로고
    • Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
    • Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
    • (1994) Cancer Res , vol.54 , pp. 4855-4878
    • Greenblatt, M.S.1    Bennett, W.P.2    Hollstein, M.3
  • 14
    • 58049195581 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway
    • Zenz T, Benner A, Döhner H, et al. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle. 2008;7:3810-3814.
    • (2008) Cell Cycle , vol.7 , pp. 3810-3814
    • Zenz, T.1    Benner, A.2    Döhner, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.